The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq gained +2% and touched another new all-time
high. Short-term support for both indices remains at their respective 10-DMA (5,184/16,242) followed by the rising 21-DMA
(5,136/16,117). The distribution day count declined to four and seven, respectively, with another day set to expire on each index after
the close on Monday.
Author: Raj Gupta
O’Neil Health Care Weekly
XLV has been consolidating for four weeks, pulling back 73bps last week and now narrowly below its 21-DMA ($145.56). Support
below this level is the rising 50-DMA ($143.20). We continue to recommend an equal-weight sector positioning given its RS line
remains in a longer-term downtrend.
Market View
The U.S. market remains in a
O’Neil Health Care Weekly
XLV traded relatively flat last week, still holding support along its rising 21-DMA ($145.19). Support below this level is the rising 50-DMA
($142.30). We continue to recommend an equal-weight sector positioning given its RS line remains in a longer-term downtrend and
has yet to make short-term progress. With that said, we believe any sustained pullback in the market will result in relative
improvement in the sector.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq bounced off 21-DMA support (5,055/15,929) mid-week but staged a downside reversal on Friday. However, both indices remain near all-time highs and above 21-DMA support. The distribution day count increased to eight on the Nasdaq and remains at five on the S&P 500 with one day expiring on each index next week.
O’Neil Health Care Weekly
XLV declined 1% last week, but held 21-DMA ($144.64) support Friday. We continue to recommend an equal-weight sector
positioning as its RS line remains in a longer-term downtrend versus the broader market. Within the sector, we continue to
recommend an overweight positioning in Medical Technology and Biotech.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 finished strong and closed the week up 1%, while the Nasdaq gained 1.7%. Neither index has any remaining resistance as the S&P 500 continued further into all-time highs and the Nasdaq surpassed its 2021 peak of 16,212 for the first time. Indices have the first level of support at their 10-DMA (5,059/15,935). Below that, the 21-DMAs are the most major level of support (5,016/15,819). The distribution day count on each index stands at six, with one set to expire in the coming week.
O’Neil Health Care Weekly
XLV gained 1.5%, rallying for a fourth straight week as it trends along support at its 10-DMA ($145.41) and 21-DMA ($143.31). Despite
good absolute performance, we continue to recommend an equal-weight sector positioning as its RS line remains in a longer-term
downtrend versus the broader market.
Market View
The U.S. market remains in a Confirmed Uptrend. Indices rallied off moving average support as the S&P 500 remains at all-time highs while the Nasdaq is testing resistance along ~16,000. Support for the S&P 500 and Nasdaq is at their respective rising 10-DMA (5,018/15,808), followed by the 21-DMA (4,969/15,660). The distribution day count on each index stands at five.
O’Neil Health Care Weekly
XLV gained 1.1% last week continuing its move into new all-time highs. The 21-DMA ($142.42) has been acting as a solid level of
near-term support since November. The RS line has risen from lows, but has yet to make a higher high, warranting an equal-tounderweight sector positioning, which will likely change should the broader tape come under pressure.